October 1, 2023 - In a special feature by Drug Development and Delivery, Dr. Anquetil, PHD, MBA, CEO and Founder of Portal Instruments, explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability.
Portal Instruments: PFS Addresses Variety of Injection Challenges
October 1, 2023 - Portal Instruments, led by Dr. Patrick Anquetil, PHD, MBA, CEO and Founder, is setting a new standard in drug delivery with its groundbreaking PRIME device. In a special feature, Dr. Anquetil explains how PRIME not only prioritizes patient comfort and compliance but also aligns with environmental sustainability. This needle-free injection device offers a revolutionary approach to high viscosity therapies, addressing challenges such as needle fear, injection pain, and the need for real-time tracking and reminders.
Read the full Drug Development and Delivery special feature here.
October 2019 - Drug development is a costly, long, and uncertain endeavor. The cost of taking a drug from preclinical research through market approval is $2.6 billion according to a recent study by the Tufts Center for the Study of Drug Development.
January 18, 2022 - Despite recent innovations, like the launch in Europe of the first electromechanical reusable and connected auto-injector (UCB’s CIMZIA ava Connect® in early 2021), almost all new biologic drugs are launched with specific and undifferentiated self-injection options...
October 2024 - Portal presented the poster "Addressing the Challenges of Highly Viscous Formulations Using a Needle-Free Technology" at the The PDA Universe of Pre-Filled Syringes and Injection Devices Conference in Arizona.
Please fill out the details below and we will get back to you shortly.